Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013

Download as PDF

- Conference call with investment community on Thursday, March 7, 2013 -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full year 2012 on Wednesday, March 6, 2013 after market close. The announcement will be followed by a conference call with the investment community, on Thursday, March 7, 2013, at 8:30 a.m. EST to provide a business update and discuss its financial and operational results.

Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until March 21, 2013. The conference call can be accessed as follows:

 
CONFERENCE CALL INFORMATION
TO PARTICIPATE LIVE:     TO LISTEN TO A REPLAY:
Date:

Time:

 

Toll-free (U.S.) Dial in # :

International Dial in # :

    March 7, 2013

8:30 a.m. EST

 

(877) 407-8031

(201) 689-8031

    Available until:

Toll-free (U.S.) Dial in # :

International Dial in # :

 

Replay passcode:

Account #:

Conference ID #

    March 21, 2013

(877) 660-6853

(201) 612-7415

 

 

268

410082

           

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, Sr. VP & CFO
(614) 822-2330

Source: Navidea Biopharmaceuticals, Inc.

Released March 4, 2013